Renowned Scientist from ADMETRx Joins Advisory Board of Locus Pharmaceuticals

KALAMAZOO, Mich.--(Business Wire)--
ADMETRx, a Michigan-based privately held Contract Research
Organization (CRO) that provides customized solutions to the
pharmaceutical and biotechnology industries in making preclinical drug
candidate advancement decisions, announced that company co-founder,
Philip S. Burton, PhD, has accepted an appointment to the advisory
board of Locus Pharmaceuticals. With 25 years of experience in
medicinal and biopharmaceutical chemistry and drug absorption, Dr.
Burton, also the CEO and CSO of ADMETRx, is an internationally
recognized thought-leader in modeling drug absorption and a frequent
invited lecturer to numerous national and international symposia.

"Dr. Burton and the team at ADMETRx bring to the Locus Advisory
Board a broad and deep understanding of the impact of ADME and
pharmacokinetics upon advancing successful drug discovery candidates,"
says Jeff Wiseman, PhD, Chief Technology Officer at Locus
Pharmaceuticals. "We feel that Dr. Burton will be a key advisor to our
drug discovery and development programs as we move our internal
projects into clinical trials."

ADMETRx was founded by Dr. Burton and co-founder Jay T. Goodwin,
PhD (company President and COO) in 2003. Committed to redefining the
drug discovery process, ADMETRx assists pharma and biotech clients in
optimizing their lead selection decision-making. Focusing specifically
on the ADME research needs of their customers, the company addresses a
wide range of relevant issues, from managing capacity challenges to
developing sophisticated multi-criteria optimization approaches. Its
high quality data integration via advanced techniques and technologies
leads to cost savings and improved drug discovery effectiveness.

Locus Pharmaceuticals is also a privately held company that was
founded as Locus Discovery in 1999. A world leader in computational
drug design, the company's core technology is a fragment-based,
computational approach, which it has combined with highly integrated
medicinal chemistry, crystallography and biology capabilities to
create a unique drug design and development platform. Locus is using
its capabilities to develop its own compounds and has also entered
into drug design/development collaborations with several pharma and
biotech partners.

Committed to assisting their clients achieve their drug discovery
goals, both ADMETRx and Locus Pharmaceuticals have dynamic leadership
teams composed of scientific experts and business leaders who have
longstanding experience and success in the pharmaceutical and
biotechnology industries.

ADMETRx
Jay T. Goodwin, PhD
269-372-3272
jtgoodwin@admetrx.com
www.admetrx.com

Copyright Business Wire 2008